Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA57
|
| gptkbp:brand |
Sotyktu
|
| gptkbp:CASNumber |
1609392-27-9
|
| gptkbp:chemicalClass |
pyridazine derivative
|
| gptkbp:developer |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:hasMolecularFormula |
C22H19F2N5O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
deucravacitinib
|
| gptkbp:legalStatus |
Prescription only
|
| gptkbp:mechanismOfAction |
TYK2 inhibitor
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:PubChem_CID |
121489515
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:folliculitis
diarrhea headache hypertension acne herpes simplex upper respiratory tract infection mouth ulcers |
| gptkbp:target |
gptkb:TYK2
|
| gptkbp:UNII |
6Z1Y2V4S2E
|
| gptkbp:usedFor |
plaque psoriasis
|
| gptkbp:bfsParent |
gptkb:TYK2
|
| gptkbp:bfsLayer |
8
|